<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160727</url>
  </required_header>
  <id_info>
    <org_study_id>CARTOnG-2104</org_study_id>
    <nct_id>NCT05160727</nct_id>
  </id_info>
  <brief_title>Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer</brief_title>
  <official_title>A Multicenter Phase II Clinical Study of Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Inoperable Recurrence and Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the efficacy of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR&#xD;
      inoperable recurrent and metastatic colorectal cancer patients; To evaluate the safety and&#xD;
      tolerability of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR inoperable&#xD;
      recurrent and metastatic colorectal cancer; To evaluate the radiosensitization effects of&#xD;
      Tslelizumab and irinotecan;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>18 weeks after treatment completion</time_frame>
    <description>in radiation field</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Mismatch Repair-proficient</condition>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Microsatellite Stable</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent Chemoradiotherapy:&#xD;
Radiation: The dose is determined according to the treatment site and the purpose of treatment.&#xD;
Irinotecan: 80mg/m2/w (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2/w (UGT1A1*28 and *6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1*28 and *6: 7/7+GG or 6/6+AA or 6/7+GA) Tislelizumab: 200mg ivgtt d1 q3w&#xD;
Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w. Tislelizumab: 200mg ivgtt d1 q3w. Efficacy assessment every 3 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200mg ivgtt d1 q3w</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Concurrent Chemoradiotherapy:&#xD;
Irinotecan: 80mg/m2/w (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2/w (UGT1A1*28 and *6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1*28 and *6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>radiotherapy</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary signing of informed consent;&#xD;
&#xD;
          2. Aged 18-75 years old, regardless of gender;&#xD;
&#xD;
          3. Histologically confirmed as inoperable recurrent or metastatic colorectal&#xD;
             adenocarcinoma;&#xD;
&#xD;
          4. Previously received oxaliplatin and fluorouracil based chemotherapy; No previous&#xD;
             treatment with irinotecan;&#xD;
&#xD;
          5. NGS sequencing or immunohistochemistry prompts MSS/pMMR&#xD;
&#xD;
          6. At least one measurable lesion;&#xD;
&#xD;
          7. Palliative radiotherapy is required for clinical evaluation (except radiotherapy for&#xD;
             bone or brain metastasis);&#xD;
&#xD;
          8. ECOG scores 0-2;&#xD;
&#xD;
          9. Expected survival ≥ 6 months;&#xD;
&#xD;
         10. The organ function of the patient was normal within 7 days before treatment, and the&#xD;
             function of important organs met certain requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding women;&#xD;
&#xD;
          2. There were primary lesions or metastases in the radiation field and had received&#xD;
             radiotherapy before;&#xD;
&#xD;
          3. Previously received PD-1, PD-L1 or PD-L2 for any indication;&#xD;
&#xD;
          4. Those with other history of malignant disease in the past 5 years, except for cured&#xD;
             skin cancer and cervical carcinoma in situ;&#xD;
&#xD;
          5. If there is an uncontrolled history of epilepsy, central nervous system disease or&#xD;
             mental disorder, the investigator may determine that the clinical severity may hinder&#xD;
             the signing of informed consent or affect the patient's oral medication compliance;&#xD;
&#xD;
          6. Clinically severe (ie, active) heart disease, such as symptomatic coronary heart&#xD;
             disease, New York Heart Association (NYHA) class II or more severe congestive heart&#xD;
             failure or severe arrhythmia requiring medication intervention (see appendix 12), or a&#xD;
             history of myocardial infarction in the last 12 months;&#xD;
&#xD;
          7. Organ transplantation requires immunosuppressive therapy Severe uncontrolled recurrent&#xD;
             infections, or other serious uncontrolled concomitant diseases;&#xD;
&#xD;
          8. Subject blood routine and biochemical indicators do not meet the following criteria:&#xD;
             hemoglobin ≥ 90g / L; absolute neutrophil count (ANC)≥ 1.5 × 109 / L; Alanine&#xD;
             transaminase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of&#xD;
             normal; alkaline phosphatase (ALP).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <phone>0571-88128142</phone>
    <phone_ext>+86</phone_ext>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ning Zhou, MD</last_name>
    <phone>0571-88128142</phone>
    <phone_ext>+86</phone_ext>
    <email>zhouning@zjcc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji zhu, MD</last_name>
      <phone>0571-88128142</phone>
      <phone_ext>+86</phone_ext>
      <email>leo.zhu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Ning Zhou, MD</last_name>
      <phone>0571-88128142</phone>
      <phone_ext>+86</phone_ext>
      <email>zhouning@zjcc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Ji Zhu, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tislelizumab</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>mismatch repair-proficient</keyword>
  <keyword>microsatellite stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

